CA3110520A1 - Thyroid hormone receptor beta agonist compounds - Google Patents
Thyroid hormone receptor beta agonist compounds Download PDFInfo
- Publication number
- CA3110520A1 CA3110520A1 CA3110520A CA3110520A CA3110520A1 CA 3110520 A1 CA3110520 A1 CA 3110520A1 CA 3110520 A CA3110520 A CA 3110520A CA 3110520 A CA3110520 A CA 3110520A CA 3110520 A1 CA3110520 A1 CA 3110520A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- compound
- alkyl
- methyl
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722312P | 2018-08-24 | 2018-08-24 | |
| US62/722,312 | 2018-08-24 | ||
| US201962867117P | 2019-06-26 | 2019-06-26 | |
| US62/867,117 | 2019-06-26 | ||
| PCT/US2019/047968 WO2020041741A1 (en) | 2018-08-24 | 2019-08-23 | Thyroid hormone receptor beta agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3110520A1 true CA3110520A1 (en) | 2020-02-27 |
Family
ID=69584321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3110520A Pending CA3110520A1 (en) | 2018-08-24 | 2019-08-23 | Thyroid hormone receptor beta agonist compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10800767B2 (https=) |
| EP (1) | EP3840755B1 (https=) |
| JP (2) | JP7579253B2 (https=) |
| CN (1) | CN112805005A (https=) |
| AU (2) | AU2019325656B2 (https=) |
| CA (1) | CA3110520A1 (https=) |
| MA (1) | MA53448A (https=) |
| TW (1) | TWI837169B (https=) |
| WO (1) | WO2020041741A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI840423B (zh) | 2018-10-12 | 2024-05-01 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| GEP20247637B (en) | 2019-05-08 | 2024-06-25 | Aligos Therapeutics Inc | Modulators of thr-b and methods of use thereof |
| WO2020228577A1 (zh) * | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN114375193B (zh) | 2019-09-12 | 2024-05-14 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
| CN114437034A (zh) * | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| CN116670118B (zh) | 2020-11-13 | 2026-02-06 | 伊尼制药公司 | 二氯苯酚hsd17b13抑制剂及其用途 |
| CN114621207B (zh) * | 2020-12-11 | 2025-02-11 | 广东东阳光药业股份有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| CA3212130A1 (en) * | 2021-03-03 | 2022-09-09 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2022194278A1 (zh) * | 2021-03-19 | 2022-09-22 | 南京明德新药研发有限公司 | 双环苯酚类化合物及其应用 |
| CN117624154A (zh) * | 2021-03-19 | 2024-03-01 | 南京明德新药研发有限公司 | 双环吡啶酮类化合物及其应用 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| CN116554063B (zh) * | 2023-05-23 | 2025-03-07 | 江苏省农用激素工程技术研究中心有限公司 | 氟胺磺隆中间体的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7230031B2 (en) | 2002-01-30 | 2007-06-12 | Kissei Pharmaceutical Co., Ltd. | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| US7572799B2 (en) * | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| PL1919878T3 (pl) * | 2005-07-21 | 2011-03-31 | Hoffmann La Roche | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
| WO2007132475A1 (en) | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
| US8394811B2 (en) * | 2007-04-18 | 2013-03-12 | Molsoft Llc | Hydrazide compounds as thyroid hormone receptor modulators and uses thereof |
| TWI698430B (zh) * | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| CN109574995B (zh) | 2018-01-23 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| CN111801324B (zh) | 2018-06-12 | 2021-10-22 | 四川海思科制药有限公司 | 甲状腺激素受体激动剂及其用途 |
| US12391677B2 (en) | 2018-10-12 | 2025-08-19 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
-
2019
- 2019-08-23 CA CA3110520A patent/CA3110520A1/en active Pending
- 2019-08-23 EP EP19852050.4A patent/EP3840755B1/en active Active
- 2019-08-23 TW TW108130298A patent/TWI837169B/zh active
- 2019-08-23 US US16/549,979 patent/US10800767B2/en active Active
- 2019-08-23 AU AU2019325656A patent/AU2019325656B2/en active Active
- 2019-08-23 MA MA053448A patent/MA53448A/fr unknown
- 2019-08-23 WO PCT/US2019/047968 patent/WO2020041741A1/en not_active Ceased
- 2019-08-23 JP JP2021533405A patent/JP7579253B2/ja active Active
- 2019-08-23 CN CN201980066702.0A patent/CN112805005A/zh active Pending
-
2024
- 2024-08-29 US US18/818,705 patent/US20250236615A1/en active Pending
- 2024-10-25 JP JP2024187991A patent/JP7846735B2/ja active Active
-
2025
- 2025-07-22 AU AU2025206402A patent/AU2025206402A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019325656B2 (en) | 2025-04-24 |
| TWI837169B (zh) | 2024-04-01 |
| MA53448A (fr) | 2022-04-20 |
| EP3840755A4 (en) | 2022-04-20 |
| JP2025020206A (ja) | 2025-02-12 |
| CN112805005A (zh) | 2021-05-14 |
| JP7846735B2 (ja) | 2026-04-15 |
| EP3840755B1 (en) | 2026-02-18 |
| EP3840755A1 (en) | 2021-06-30 |
| JP2021535207A (ja) | 2021-12-16 |
| AU2025206402A1 (en) | 2025-08-07 |
| US10800767B2 (en) | 2020-10-13 |
| AU2019325656A1 (en) | 2021-03-11 |
| US20200062742A1 (en) | 2020-02-27 |
| TW202023560A (zh) | 2020-07-01 |
| JP7579253B2 (ja) | 2024-11-07 |
| WO2020041741A1 (en) | 2020-02-27 |
| US20250236615A1 (en) | 2025-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3110520A1 (en) | Thyroid hormone receptor beta agonist compounds | |
| JP7624025B2 (ja) | アミノ酸化合物および使用方法 | |
| JP7646632B2 (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| CN112839655B (zh) | 甲状腺激素受体β促效剂化合物 | |
| CA3212130A1 (en) | Thyroid hormone receptor beta agonist compounds | |
| EP4482579B1 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| HK40037094A (en) | Amino acid compounds and methods of use | |
| HK40037094B (en) | Amino acid compounds and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240730 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240730 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240730 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250210 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250210 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250410 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250729 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250808 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250922 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250922 |